Loading Valuation Snapshot...
Stock DNA
Pharmaceuticals & Biotechnology
INR 12,688 Cr ()
61.00
31
0.00%
0.00
0.00%
16.92
Revenue and Profits:
Net Sales:
476 Cr
(Quarterly Results - Dec 2025)
Net Profit:
73 Cr
Total Returns (Price + Dividend) 
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
17.27%
0%
17.27%
6 Months
0%
0%
0.0%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Rubicon Research for the last several years.
Risk Adjusted Returns v/s 
Returns Beta
Beta has not been calculated since enough price history is not available
News
No Recent News for the Company
Announcements 
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
31-Mar-2026 | Source : BSEAllotment of Equity shares pursuant to exercise of ESOPs
Closure of Trading Window
31-Mar-2026 | Source : BSEClosure of Trading Window
Shareholder Meeting / Postal Ballot-Scrutinizers Report
16-Mar-2026 | Source : BSEScrutinizers Report
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
6.94
Debt to EBITDA (avg)
1.56
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.27
Tax Ratio
24.96%
Dividend Payout Ratio
0.23%
Pledged Shares
0
Institutional Holding
17.44%
ROCE (avg)
22.12%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
61
Industry P/E
31
Price to Book Value
16.85
EV to EBIT
55.50
EV to EBITDA
48.92
EV to Capital Employed
10.92
EV to Sales
12.30
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
19.68%
ROE (Latest)
22.13%
Technicals key factors
Indicator
Weekly
Monthly
MACD
RSI
Bearish
Bollinger Bands
Bullish
KST
Dow Theory
Mildly Bullish
OBV
No Trend
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Promoters
Pledged Promoter Holdings
None
Mutual Funds
Held by 9 Schemes (6.61%)
FIIs
Held by 42 FIIs (7.99%)
Promoter with highest holding
General Atlantic Singapore Rr Pte Ltd (35.97%)
Highest Public shareholder
Shivanand Shankar Mankekar Huf (13.57%)
Individual Investors Holdings
2.71%
Quarterly Results Snapshot (Standalone) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
301.71
336.47
-10.33%
Operating Profit (PBDIT) excl Other Income
62.24
79.11
-21.32%
Interest
7.51
9.21
-18.46%
Exceptional Items
0.00
0.00
Standalone Net Profit
37.18
45.81
-18.84%
Operating Profit Margin (Excl OI)
20.63%
23.51%
-2.88%
Values in Rs Cr.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -10.33% vs 21.02% in Sep 2025
Standalone Net Profit
QoQ Growth in quarter ended Dec 2025 is -18.84% vs 30.33% in Sep 2025
Annual Results Snapshot (Standalone) - Mar'25
Mar'25
Change(%)
Net Sales
1,073.84
NA
NA
Operating Profit (PBDIT) excl Other Income
269.89
NA
NA
Interest
34.29
NA
NA
Exceptional Items
0.00
NA
NA
Standalone Net Profit
167.54
NA
NA
Operating Profit Margin (Excl OI)
25.13%
NA%
NA
Values in Rs Cr.
Net Sales
Not Applicable: The company has declared_date for only one period
Standalone Net Profit
Not Applicable: The company has declared_date for only one period